← FDA DRUG APPROVALS

FDA NDA · NDA020118

SUPRANE

desflurane

Sponsor: BAXTER HLTHCARE

APPLICATION
NDA020118
TYPE
NDA
ORIGINAL APPROVAL
1992-09-18
LATEST ACTION
2022-11-01
ROUTE
RESPIRATORY (INHALATION), INHALATION
DOSAGE FORM
LIQUID
MARKETING STATUS
Prescription

Products

SUPRANE · ReferencePrescription
DESFLURANE 100% · LIQUID · INHALATION

Approval history

2022-11-01Labeling · Supplement 26 · standardLetterAP
2019-03-01Manufacturing (CMC) · Supplement 22 · standardLabelAP
2019-03-01Labeling · Supplement 23 · standardLabelAP
2017-04-27Labeling · Supplement 24 · standardLetterAP
2016-11-04Labeling · Supplement 21 · standardLetterAP
2015-02-26Labeling · Supplement 20 · standardLetterAP
2013-09-27Manufacturing (CMC) · Supplement 19 · standardAP
2013-09-23Labeling · Supplement 18 · standardLetterAP
2010-04-05Labeling · Supplement 17 · standardLabelAP
2009-04-14Labeling · Supplement 16 · standardLabelAP
2006-12-15Efficacy · Supplement 12 · priorityPediatric Medical ReviewAP
2006-08-14Labeling · Supplement 11 · standardLetterAP
2006-05-08Labeling · Supplement 10 · standardLabelAP
2002-08-08Manufacturing (CMC) · Supplement 8 · standardReviewAP
1999-12-02Manufacturing (CMC) · Supplement 7 · standardReviewAP
1998-12-09Manufacturing (CMC) · Supplement 5 · standardAP
1997-12-16Manufacturing (CMC) · Supplement 4 · standardAP
1995-07-05Labeling · Supplement 2 · standardAP
1993-03-26Manufacturing (CMC) · Supplement 1 · standardAP
1992-09-18Type 1 - New Molecular Entity · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →